

News Release
For Immediate Release

**Orient Europharma announces annual report -- EPS rises 17 percent to
NT\$4.04**

Taipei, Taiwan, Feb. 24, 2010 -- Orient Europharma Co. Ltd. (OE, Taiwan OTC: 4120) today announced that its board of directors approved the company's 2009 financial results.

Despite the economic crisis, the company performed well in 2009 and continued to expand. OE's growth is contributed mainly by its business operations in Asia.

OE's sales grew at a stable rate in 2009. Consolidated net sales grew 8.6 percent to NT\$3.878 billion. Net sales in Taiwan reached NT\$3.201 billion -- a 7.3 percent increase compared with the previous year. Gross profits amounted to NT\$1.157 billion which is a 11% gain from last year. Earnings per share (EPS) increased 17 percent to NT\$4.04.

In addition, the investment income on equity-method investees, mainly contributed by OE subsidiaries, doubled to NT\$39.11 million last year.

With an elderly population surpassing 10 percent, Taiwan's demand for drugs to treat hypertension, diabetes, cholesterol, and other chronic conditions has grown accordingly. OE's pharma division saw a sales increase of 12 percent in 2009 led by hypertension drug Zanidip, testosterone gel Androgel, and diabetes combination therapy GlucoMet. Furthermore, newly updated drugs for asthma and diabetes will arrive on the

market in the second quarter which will cater to the growing group of patients and offer them new alternative treatments.

According to statistics by Taiwan's Bureau of National Health Insurance, oncology drug expenses grew 10 percent last year to exceed NT\$15 billion. Seeing the significant growth in demand, the oncology division will remain as one of OE's main focuses. Sales of the oncology division's Navelbine Oral, a lung cancer and metastatic breast cancer oral treatment, surpassed last year by 20 percent.

Sales of the company's dermo-cosmetic division grew nearly 20 percent in 2009 thanks to the continuing popularity of OE's injectable hyaluronic acid as well as its four brand names, off-the-shelf products. In 2010, the company expects to stay competitive in the market with the introduction of a new series of organic dermo-cosmetic anti-aging products.

The consumer healthcare division's sales grew by more than 40 percent due to popular products such as KariMed health supplements as well as Buccotherm thermal springwater dental sprays and toothpastes.

Moreover, OE's subsidiary Orient Pharma will soon inaugurate a new plant that was designed to conform to international standards. The new plant is expected to start operating this year.

Orient Pharma has been formally recognized by Taiwan's government as a biotech and new pharmaceutical company. The new plant will focus on the production of drugs, new drug R&D, and conducting clinical trials. It will also endeavor to obtain

exclusive manufacturing rights in Taiwan of patented prescription drugs by international pharmaceutical companies in order to increase OE's output.

Looking forward, OE will continue to expand its business in the local and Asian markets as well as the rest of the world.